Geno10X Biosciences develops AI-powered rapid disease tests for infectious diseases. Their platform aims to provide accurate, non-invasive results to identify patients needing advanced care, improving the testing process for both patients and providers.
Funding
Funding not disclosed
Founders
Product
Problem
Current infectious disease testing methods often involve invasive procedures, lengthy processing times, and centralized lab analysis, creating delays in diagnosis and treatment. Traditional testing approaches can also be expensive and require specialized equipment, limiting accessibility in point-of-care settings.
Solution
Geno10X Biosciences is developing an AI-powered platform for rapid disease detection, utilizing non-invasive sample collection and decentralized point-of-care testing (POCT) stations. The platform combines proprietary dyes, quantum dots, and next-generation imaging sensors to detect molecular biomarkers in samples without requiring PCR amplification. Paired with custom-built AI algorithms, the platform aims to accurately predict disease risk, enabling timely intervention by physicians at a fraction of the cost and time of traditional testing. The system is designed to identify individuals in need of advanced care, streamlining the care journey for both patients and providers.
Target Audience
The primary target audience includes healthcare clinics, diagnostic labs, hospitals, and local and provincial governments seeking rapid, accurate, and accessible disease testing solutions.
Features
- Non-invasive sample collection for patient comfort and ease of use
- Decentralized Point of Care Testing (POCT) stations for rapid sample processing and readout
- Proprietary dyes, quantum dots, and next-generation imaging sensors for high sensitivity and specificity
- AI-powered algorithms for accurate disease risk prediction
- Detection of molecular biomarkers in samples without PCR amplification
- Rapid test results for timely clinical decision-making